Onyx Pharmaceuticals Shareholder Alert: The Briscoe Law Firm and Powers Taylor, LLP Investigate Merger with Amgen, Inc.
27 August 2013 - 2:54AM
Business Wire
Former United States Securities and Exchange Commission attorney
Willie Briscoe and the securities litigation firm of Powers Taylor,
LLP are investigating the merger of Onyx Pharmaceuticals, Inc.
(“Onyx”) (NasdaqGS: ONXX) with Amgen, Inc. for shareholders. Under
the terms of the proposed merger agreement, valued at approximately
$10.4 billion, Onyx shareholders are expected to receive $125 per
share of Onyx common stock owned, well below the 52-week high of
$136.87.
If you are an affected investor, and you want to learn more
about the lawsuit or join the action, please contact Willie Briscoe
at The Briscoe Law Firm, PLLC, (214) 239-4568, via email at
WBriscoe@TheBriscoeLawFirm.com or Zach Groover at Powers Taylor,
LLP, toll free (877) 728-9607 or via e-mail at
shareholder@powerstaylor.com. There is no cost or fee to you.
The Onyx sale investigation centers on whether shareholders are
receiving adequate compensation for their shares in the proposed
deal, whether the transaction properly values Onyx stock, and
whether Onyx’s board attempted to obtain the highest share price
for all shareholders prior to agreeing to the deal.
The Briscoe Law Firm, PLLC is a full service business litigation
and shareholder rights advocacy firm with more than 20 years of
experience in complex litigation and transactional matters.
Powers Taylor, LLP is a boutique litigation law firm that
handles a variety of complex business litigation matters, including
claims of investor and stockholder fraud, shareholder oppression,
shareholder derivative suits, and security class actions.
The Briscoe Law Firm, PLLCWillie Briscoe,
214-239-4568WBriscoe@TheBriscoeLawFirm.comorPowers Taylor, LLPZach
Groover, 877-728-9607shareholder@powerstaylor.com
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Onyx Pharmaceuticals, Inc. (MM) (NASDAQ): 0 recent articles
More Powers Taylor, LLP News Articles